Receptor activator of nuclear factor kappa-B–TNF receptor-associated factor 6 protein–protein interaction interface (RANK–TRAF6 PPI interface)

The Receptor activator of nuclear factor kappa-B (RANK)–TNF receptor-associated factor 6 (TRAF6) protein–protein interaction (PPI) interface is a critical signaling junction that mediates osteoclastogenesis and bone resorption. RANK, a transmembrane receptor expressed on osteoclast precursors, lacks intrinsic kinase activity and must recruit the E3 ubiquitin ligase TRAF6 to its cytoplasmic domain to initiate downstream signaling (Ye et al., 2002, Nature). This interaction is triggered by the binding of RANK ligand (RANKL) and leads to the activation of the NF-κB, MAPK, and NFATc1 pathways, which are essential for the differentiation and survival of bone-resorbing osteoclasts (UniProt Q9Y6Q6). Pathological overactivity of the RANK–TRAF6 axis is a hallmark of bone-destructive diseases such as osteoporosis, rheumatoid arthritis, and bone metastasis (Park et al., 2015, JBMR). Unlike systemic RANKL inhibition, which can have broad effects, targeting the specific PPI interface between RANK and TRAF6 offers a strategy to selectively inhibit bone resorption while potentially sparing other TRAF6-dependent immune functions, such as those involved in Toll-like receptor signaling (Walsh & Choi, 2014, Frontiers in Immunology). Current drug discovery efforts focus on small molecules and peptidomimetics that competitively bind to the TRAF6-binding motifs on RANK to disrupt this complex (UniProt Q9Y4K3).

Other names

RANK-TRAF6 interactionRANK-TRAF6 signaling complexRANK-TRAF6 binding siteTNFRSF11A-TRAF6 interface

Disruption of the recruitment of the TRAF6 adapter protein to the cytoplasmic tail of the RANK receptor, preventing the assembly of the signalosome required for osteoclast differentiation.